UA92580C2 - Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение - Google Patents

Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение

Info

Publication number
UA92580C2
UA92580C2 UA20041209866A UA20041209866A UA92580C2 UA 92580 C2 UA92580 C2 UA 92580C2 UA 20041209866 A UA20041209866 A UA 20041209866A UA 20041209866 A UA20041209866 A UA 20041209866A UA 92580 C2 UA92580 C2 UA 92580C2
Authority
UA
Ukraine
Prior art keywords
therapeutic
antibody
human
antibodies specific
diagnostic uses
Prior art date
Application number
UA20041209866A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эндрю Джордж Попплвэлл
Саймон Питер Тикл
Хедер Маргарет Ледимен
Original Assignee
Ю-Си-Би Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA92580(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ю-Си-Би Фарма С.А. filed Critical Ю-Си-Би Фарма С.А.
Publication of UA92580C2 publication Critical patent/UA92580C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к антителу, которое специфически связывается с СD22. Раскрытые химерические и гуманизированные антитела, полученные из исходного мышиного антитела 5/44. Изобретение также относится к последовательности ДНК, который кодирует тяжелую и легкую цепь антитела, вектора, клетки-хозяина, способа получения антитела, способа получения фармацевтической и диагностической композиции, применение данного антитела для лечения патологии, опосредованной клетками, которые экспрессируют CD22.
UA20041209866A 2002-05-02 2003-05-02 Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение UA92580C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products

Publications (1)

Publication Number Publication Date
UA92580C2 true UA92580C2 (ru) 2010-11-25

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041209866A UA92580C2 (ru) 2002-05-02 2003-05-02 Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение

Country Status (35)

Country Link
US (8) US7355011B2 (ru)
EP (1) EP1504035B9 (ru)
JP (3) JP4486494B2 (ru)
KR (3) KR101156796B1 (ru)
CN (3) CN103172742B (ru)
AT (1) ATE462729T3 (ru)
AU (1) AU2003223007C1 (ru)
BE (1) BE2017C068I2 (ru)
CA (1) CA2484420C (ru)
CO (1) CO5631451A2 (ru)
CY (3) CY1110134T1 (ru)
DE (1) DE60331910D1 (ru)
DK (1) DK1504035T6 (ru)
EC (1) ECSP045470A (ru)
ES (1) ES2341708T7 (ru)
FR (1) FR17C1062I2 (ru)
GB (1) GB0210121D0 (ru)
HK (2) HK1071762A1 (ru)
HU (2) HUS1700055I1 (ru)
IL (1) IL164923A (ru)
LT (2) LTC1504035I2 (ru)
LU (2) LUC00058I2 (ru)
MX (1) MXPA04010787A (ru)
NL (1) NL300920I2 (ru)
NO (1) NO336201B3 (ru)
NZ (1) NZ536757A (ru)
PL (1) PL218433B1 (ru)
PT (1) PT1504035E (ru)
RU (1) RU2342401C2 (ru)
SG (1) SG161744A1 (ru)
SI (1) SI1504035T1 (ru)
TW (1) TWI324161B (ru)
UA (1) UA92580C2 (ru)
WO (1) WO2003093320A2 (ru)
ZA (1) ZA200408851B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1448584B1 (en) * 2001-09-26 2010-05-19 The Government of the United States of America as represented by The Secretary of Health and Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT1507556T (pt) 2002-05-02 2016-09-28 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SV2006002258A (es) * 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2644906C (en) * 2006-03-06 2016-05-10 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RS53168B (en) * 2006-05-30 2014-06-30 Genentech Inc. Antibodies and Immunoconjugates and Their Use
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
CA2871764A1 (en) * 2012-04-26 2013-10-31 Gerhard Frey Anti-cd22 antibodies
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
ES2718903T3 (es) * 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
KR20160072268A (ko) 2013-11-04 2016-06-22 화이자 인코포레이티드 항-efna4 항체-약물 접합체
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN114958764A (zh) * 2015-04-08 2022-08-30 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
AU2019245285A1 (en) * 2018-03-30 2020-11-12 Eureka Therapeutics, Inc. Constructs targeting CD22 and uses thereof
US20230174654A1 (en) * 2020-04-02 2023-06-08 Nanjing Iaso Biotherapeutics Co., Ltd. Fully human anti-human cd22 chimeric antigen receptor and application thereof
CN114106177B (zh) * 2020-08-27 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
WO2023027534A1 (ko) * 2021-08-27 2023-03-02 주식회사 펩트론 신규 항 muc1항체 및 이의 용도
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1013666B1 (en) * 1990-06-27 2006-05-10 Princeton University Protein complex p53/p90
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
AU686004B2 (en) 1994-08-12 1998-01-29 Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2270288A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU740904B2 (en) 1997-03-20 2001-11-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
SI1232392T1 (en) * 1999-10-12 2003-10-31 Connex Gesellschaft Zur Optimierung Von Forschung Und Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
MXPA03000306A (es) * 2000-07-12 2004-04-05 Idec Pharma Corp Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT1507556T (pt) 2002-05-02 2016-09-28 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
GB0210121D0 (en) 2002-06-12
CN103172742A (zh) 2013-06-26
SI1504035T1 (sl) 2010-07-30
US20070059307A1 (en) 2007-03-15
LUC00058I2 (ru) 2018-02-26
PL218433B1 (pl) 2014-12-31
FR17C1062I1 (ru) 2018-02-16
AU2003223007B2 (en) 2009-07-16
SG161744A1 (en) 2010-06-29
LUC00058I1 (ru) 2017-12-27
LUC00057I2 (ru) 2018-02-26
ATE462729T3 (de) 2010-04-15
KR101156796B1 (ko) 2012-06-21
CY2017046I1 (el) 2018-12-12
PL373277A1 (en) 2005-08-22
LTPA2017044I1 (lt) 2018-01-10
NO336201B1 (no) 2015-06-15
PT1504035E (pt) 2010-06-07
DK1504035T3 (da) 2010-06-07
JP5377173B2 (ja) 2013-12-25
KR101386376B1 (ko) 2014-04-16
JP5920934B2 (ja) 2016-05-18
TW200307690A (en) 2003-12-16
CO5631451A2 (es) 2006-04-28
HK1186479A1 (zh) 2014-03-14
NO20044742L (no) 2004-12-22
HK1071762A1 (en) 2005-07-29
BE2017C068I2 (ru) 2022-08-09
WO2003093320A2 (en) 2003-11-13
IL164923A (en) 2012-03-29
WO2003093320A3 (en) 2004-02-05
US20170145114A1 (en) 2017-05-25
NZ536757A (en) 2006-06-30
RU2342401C2 (ru) 2008-12-27
EP1504035B8 (en) 2018-02-28
ES2341708T7 (es) 2018-04-11
EP1504035B1 (en) 2010-03-31
JP2006506955A (ja) 2006-03-02
US7355011B2 (en) 2008-04-08
US20110165659A1 (en) 2011-07-07
ES2341708T3 (es) 2010-06-25
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
JP2010022372A (ja) 2010-02-04
CN101134779A (zh) 2008-03-05
US8895714B2 (en) 2014-11-25
IL164923A0 (en) 2005-12-18
KR101238970B1 (ko) 2013-03-04
EP1504035B3 (en) 2017-12-20
KR20110004463A (ko) 2011-01-13
CA2484420C (en) 2014-09-16
JP4486494B2 (ja) 2010-06-23
US20100021995A1 (en) 2010-01-28
CN101134779B (zh) 2013-03-13
MXPA04010787A (es) 2005-03-07
EP1504035A2 (en) 2005-02-09
KR20050025167A (ko) 2005-03-11
US7919606B2 (en) 2011-04-05
DE60331910D1 (de) 2010-05-12
CA2484420A1 (en) 2003-11-13
AU2003223007A1 (en) 2003-11-17
CY2017046I2 (el) 2018-12-12
CN100384878C (zh) 2008-04-30
US20160326247A1 (en) 2016-11-10
AU2003223007C1 (en) 2019-08-08
JP2013230158A (ja) 2013-11-14
EP1504035B9 (en) 2018-10-17
US20210371547A1 (en) 2021-12-02
LTC1504035I2 (lt) 2022-04-11
HUS1700055I1 (hu) 2018-07-30
US20120302739A1 (en) 2012-11-29
LTPA2017043I1 (lt) 2018-01-10
DK1504035T6 (en) 2018-03-12
TWI324161B (en) 2010-05-01
US20030235869A1 (en) 2003-12-25
NL300920I1 (ru) 2018-01-03
CY2017045I1 (el) 2019-11-27
CY1110134T1 (el) 2015-01-14
FR17C1062I2 (fr) 2020-05-29
LUC00057I1 (ru) 2017-12-27
HUS1700056I1 (hu) 2018-07-30
RU2004135103A (ru) 2005-10-27
ZA200408851B (en) 2006-01-25
CY2017045I2 (el) 2019-11-27
NL300920I2 (nl) 2021-04-15
ECSP045470A (es) 2005-01-28
CN103172742B (zh) 2016-05-11
CN1662558A (zh) 2005-08-31

Similar Documents

Publication Publication Date Title
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
MY136603A (en) Biological products
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2003059951A8 (fr) Anticorps anti-igf-ir et leurs applications
TW200635946A (en) Binding proteins specific for human matriptase
AR042485A1 (es) Anticuerpo humanizado que se une al cd20 humano
WO2005049651A3 (en) Cancer diagnosis and therapy
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
BRPI0309730B8 (pt) molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica
UA85995C2 (ru) Химерическое антитело, которое специфически связывается с человеческим il-6, и фармацевтическая композиция, которая его содержит
EP1524275A3 (en) Deimmunized binding molecules to CD3
NZ600059A (en) Antibodies against cd38 for treatment of multiple myeloma